The U.S. Food and Drug Administration (FDA) has intensified its fight against the illegal peptide trade, issuing warning letters to five online sellers accused of marketing unapproved drugs. Yet, in a striking contrast, just weeks earlier the agency’s own advisory committee voted to expand the list of peptides that compounding pharmacies may legally prepare.
The Crackdown
The FDA targeted Peak Performance Peptides, Royal Peptides, NuScience Peptides, Peptide Partners, and Tex Peptides, citing violations tied to the sale of unapproved peptide‑based drugs. These companies were found advertising illicit versions of Eli Lilly’s obesity candidate retatrutide, as well as copycat formulations of Novo Nordisk’s blockbuster GLP‑1 agonist semaglutide, marketed as Wegovy and Ozempic.
Regulators warned that such injectable products “can pose risks of serious harm to users” because they bypass the body’s natural defenses. The letters also highlighted the dangers of selling peptides under the guise of “research only” while clearly marketing them for human use.
The Regulatory Shift
At the same time, momentum is building in the opposite direction. On July 23–24, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) recommended adding six popular wellness peptides to the official 503A Bulk Drug Substances List. These include BPC‑157 for tissue repair, TB‑500 for muscle recovery, KPV for gut health, MOTS‑c for mitochondrial fitness, Semax for cognitive support, and Epitalon for longevity. One peptide, Emideltide (DSIP), was rejected.
This recommendation, while not final, signals a willingness to regulate peptides more formally rather than leaving them to thrive in gray markets. If adopted, compounding pharmacies could legally prepare these substances, offering patients safer access under medical supervision.
A Market in Flux
Together, the crackdown and the committee vote illustrate the paradox at the heart of peptide medicine. On one side, regulators are shutting down black‑market sellers exploiting social media hype and consumer demand. On the other, they are cautiously opening pathways for legitimate clinical use of the very same molecules.
Industry voices stress the need for clarity. As Karsten Eastman, CEO of regulated peptide developer Sethera, told Pharmaceutical Technology, there is “a dire need for greater understanding around peptides and their potential amongst the public.”
The FDA is drawing a hard line against unsafe, underground sales while simultaneously acknowledging that peptides like BPC‑157 and Epitalon may have a legitimate future in medicine.